P. Nanni et al., THERAPY OF MURINE MAMMARY-CARCINOMA METASTASIS WITH INTERFERON-GAMMA AND MHC GENE-TRANSDUCED TUMOR-CELLS, British Journal of Cancer, 74(10), 1996, pp. 1564-1569
Gene-transfected tumour cells were used to curt mice bearing lung meta
stases by the parental, non-transduced mammary adenocarcinoma (ISA-pc)
. Repeated subcutaneous (s.c.) administrations of mitomycin C (MitC)-t
reated interferon gamma (IFN-gamma) transfectants induced a 90% inhibi
tion in the number of lung metastases. Therapeutic effect required an
intact T-cell response, as shown by the lack of efficacy in nude mice.
Autocrine stimulation by IFN-gamma induces specific modifications in
the phenotype of transfectants that acquire a high metastatic ability
and show a high expression of IFN-responsive genes; these two features
were exploited to design two experimental protocols to obtain an impr
ovement of the therapeutic effect. The increased metastatic ability of
IFN-gamma transfectants was used to deliver IFN-gamma selectively to
the lungs of mice bearing TSA-pc pulmonary metastases. A significant t
herapeutic effect was obtained when TSA-pc experimental metastases wer
e treated by repeated intravenous (i.v.) injections of MitC IFN-gamma
transfectants. Since i.v. administrations of IFN-p transfectants did n
ot induce immune memory, the therapeutical effect appeared to depend o
n the inflammatory-like response activated by local IFN release. To ex
ploit the autocrine stimulation of IFN-sensitive genes an IFN-gamma tr
ansfectant clone was subjected to a second transfection with an alloge
neic class I MHC gene (H-2K(b) or H-2D(b)). IFN-gamma plus MHC double
transfectants maintained IFN-gamma release, showed a very high express
ion of the MHC gene products, stimulated both macrophages and T cells,
and were less tumorigenic in immunocompetent mice than the parent IFN
-gamma clone. Therapeutic efficacy of double transfectant IFN-gamma pl
us H-2D(b) cells against TSA-pc was superior to single transfectants,
showing that the reaction elicited by genetically engineered cells can
be selectively tuned to increase therapeutic efficacy.